ArticleChemical science2017
Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding.
Article in Chemical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues.Biomolecules · 2026Article
- Linking molecular architecture to antibacterial functions: a chemical biology view of cyclic depsipeptides.Frontiers in chemistry · 2026Review
- Novltex: A New Class of Antibiotics with Potent Activity against Multidrug-Resistant Bacterial Pathogens─Design, Synthesis, and Biological Evaluation.Journal of medicinal chemistry · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Metabolic profiling unveils enhanced antibacterial synergy of polymyxin B and teixobactin against multi-drug resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products.Natural product reports · 2024Review
- Novel Teixobactin Analogues Show Promising In Vitro Activity on Biofilm Formation by Staphylococcus aureus and Enterococcus faecalis.Current microbiology · 2024Article
- Linearization of the Brevicidine and Laterocidine Lipopeptides Yields Analogues That Retain Full Antibacterial Activity.Journal of medicinal chemistry · 2023Article
- Isobactins:Chemical science · 2022Article
- Article
- Visualizing the mode of action and supramolecular assembly of teixobactin analogues inChemical science · 2022Article
- Synthetic Natural Product Inspired Cyclic Peptides.ACS chemical biology · 2021Article
- Emerging peptide antibiotics with therapeutic potential.Medicine in drug discovery · 2021Review
- Article
- Mode of action of teixobactins in cellular membranes.Nature communications · 2020Article
- Design, Synthesis, and Study of Lactam and Ring-Expanded Analogues of Teixobactin.The Journal of organic chemistry · 2020Article
- Thiol-ene Enabled Chemical Synthesis of TruncatedFrontiers in chemistry · 2020Article
- Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance.Journal of medicinal chemistry · 2019Review
- Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics.Nature communications · 2019Article
- Towards the Native Binding Modes of Antibiotics that Target Lipid II.Chembiochem : a European journal of chemical biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teixobactin is a highly promising antibacterial depsipeptide consisting of four d-amino acids and a rare l-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.